China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025)
China Pharma Holdings (CPHI) reported Asset Writedowns and Impairment of -$507897.0 for Q4 2025, down 53675.63% on a YoY basis from N/an in Q4 2024, and down 2107.34% quarter-over-quarter from $25302.0 in Q3 2025.
China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2015 - 2025) Analysis & Trends
China Pharma Holdings has reported Asset Writedowns and Impairment for 11 years, with the latest figure at -$507897.0 in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 53675.63% year-over-year to -$507897.0; the trailing twelve-month figure through Dec 2025 stood at -$267184.0 (down 299.35% YoY), and the FY2025 full-year result was -$1018.0, down 117.85% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at -$507897.0, down from $25302.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $213379.0 in Q1 2025, with the low at -$507897.0 in Q4 2025.
- Historically, Asset Writedowns and Impairment has averaged -$21780.8 across 5 years, with a median of -$354.0 in 2024.
- The largest YoY upside for Asset Writedowns and Impairment was 1627.9% in 2025 against a maximum downside of 53675.63% in 2025.
- China Pharma Holdings' Asset Writedowns and Impairment stood at -$250622.0 in 2021, then soared by 95.96% to -$10136.0 in 2022, then jumped by 183.31% to $8444.0 in 2023, then slumped by 88.77% to $948.0 in 2024, then plunged by 53675.63% to -$507897.0 in 2025.
- The last three Asset Writedowns and Impairment figures came in at -$507897.0 (Q4 2025), $25302.0 (Q3 2025), and $2032.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn |
| 10 | China Pharma Holdings | 18.56 Mn | 18.39 Mn | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -507,897.00 |
| Dec 31, 2025 | -507,897.00 |
| Sep 30, 2025 | 25,302.00 |
| Sep 30, 2025 | 25,302.00 |
| Jun 30, 2025 | 2,032.00 |
| Jun 30, 2025 | 2,032.00 |
| Mar 31, 2025 | 213,379.00 |
| Mar 31, 2025 | 213,379.00 |
| Dec 31, 2024 | 948.00 |
| Dec 31, 2024 | 948.00 |
| Sep 30, 2024 | -1,656.00 |
| Sep 30, 2024 | -1,656.00 |
| Jun 30, 2024 | 8,476.00 |
| Jun 30, 2024 | 8,476.00 |
| Mar 31, 2024 | 126,258.00 |
| Mar 31, 2024 | 126,258.00 |
| Dec 31, 2023 | 8,444.00 |
| Dec 31, 2023 | 8,444.00 |
| Sep 30, 2023 | -18,212.00 |
| Sep 30, 2023 | -18,212.00 |